At the Bank of America Healthcare Conference 2026, Regeneron Pharmaceuticals announced a new agreement granting them tariff relief and exemption from future US government pricing mandates through January 2029. This deal applies only to products wholly owned by Regeneron in the US, excluding some alliance products. While specific products were not named due to confidentiality, Regeneron confirmed that EYLEA and EYLEA HD are wholly owned, but DUPIXENT is not. This agreement provides Regeneron with pricing stability and cost advantages in the US market for the next several years.
Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved prog...
At the 2026 Regeneron International Science and Engineering Fair, over $7 million in awards were given to more than 1,700 young STEM students from 67+ countries. Hikaru Kuribayashi, 17, won the top $100,000 prize for his simulation program predicting...
The 2026 Regeneron International Science and Engineering Fair awarded more than $7 million to over 1,700 young STEM finalists from 67+ countries. Hikaru Kuribayashi won the top $100,000 George D. Yancopoulos Innovator Award for creating a simulation ...
